Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Disease mechanisms

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease is hypothesized to be caused by an imbalance between β-amyloid (Aβ) production and clearance that leads to Aβ accumulation in the central nervous system (CNS). Aβ production and clearance are key targets in the development of disease-modifying therapeutic agents for Alzheimer's disease. However, there has not been direct evidence of altered Aβ production or clearance in Alzheimer's disease. By using metabolic labeling, we measured Aβ42 and Aβ40 production and clearance rates in the CNS of participants with Alzheimer's disease and cognitively normal controls. Clearance rates for both Aβ42 and Aβ40 were impaired in Alzheimer's disease compared with controls. On average, there were no differences in Aβ40 or Aβ42 production rates. Thus, the common late-onset form of Alzheimer's disease is characterized by an overall impairment in Aβ clearance.

What this study adds

Evidence grade: Not rated

Using metabolic labeling, the researchers measured how fast amyloid-beta (Aβ42 and Aβ40) is made and cleared in the central nervous system of people with Alzheimer's disease and cognitively normal controls. Clearance was impaired in Alzheimer's disease while production rates did not differ on average, pointing to impaired clearance in the common late-onset form.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mawuenyega, K. G., Sigurdson, W. C., Ovod, V., Munsell, L. Y., Kasten, T. P., Morris, J. C., et al. (2010). Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease. Science. https://doi.org/10.1126/science.1197623

Vancouver

Mawuenyega KG, Sigurdson WC, Ovod V, Munsell LY, Kasten TP, Morris JC, et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease. Science. 2010. doi:10.1126/science.1197623. PMID: 21148344.

BibTeX

@article{mawuenyega2010-21148344,
  author  = {Mawuenyega, Kwasi G. and Sigurdson, Wendy C. and Ovod, Vitaliy and Munsell, Ling Y. and Kasten, Tom P. and Morris, John C. and Yarasheski, Kevin E. and Bateman, Randall John},
  title   = {{Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease}},
  journal = {Science},
  year    = {2010},
  doi     = {10.1126/science.1197623},
  pmid    = {21148344},
  url     = {https://doi.org/10.1126/science.1197623}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Why it matters

Using metabolic labeling, the researchers measured how fast amyloid-beta (Aβ42 and Aβ40) is made and cleared in the central nervous system of people with Alzheimer's disease and cognitively normal controls. Clearance was impaired in Alzheimer's disease while production rates did not differ on average, pointing to impaired clearance in the common late-onset form.

How this study scored 61/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 4 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 58 of the 95 points it could be judged on, which is 61 of 100. Total 61 of 100.58 of the 95 points we could judge = 61 of 100

Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 58 of the 95 points we could judge it on, which is 61 out of 100.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Science)
Journal's citation record 4 / 4 Science: journal h-index 1,754 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2010 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 2,079 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 115.5 citations a year over 18 year(s) since 2010
Impact for its field and year 6 / 6 Cited 62.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 4 / 4 Cited 326 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Randall John Bateman: h-index 101 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21148344)
Free to read 2 / 2 Free to read
Points 58 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 95 points we could judge it on is 61 out of 100.
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Disease mechanisms from nearby years

Also in Disease mechanisms

138 studies in the library are filed under Disease mechanisms with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disease mechanisms hub.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →